Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1119 Results

Intervention Indication Therapeutic Area Year Actions
Sacubitril/valsartan for the treatment of post-acute myocardial infarction patients with left ventricular systolic dysfucntion and/or pulmonary congestion – first line Entresto; LCZ 696 (fixed dose combination: Sacubitril; Valsartan) Post-acute myocardial infarction (MI) Cardiovascular System 2021 View  |  Download
SAGE-547 for super-refractory status epilepticus Brexanolone (SAGE-547; Zulresso) Super-refractory status epilepticus (SRSE) Neurology 2017 View  |  Download
SAR443820 for treating amyotrophic lateral sclerosis (ALS) SAR443820 (DNL788) Amyotrophic lateral sclerosis Neurology 2023 View  |  Download
Sarilumab for treating Polyarticular-course Juvenile idiopathic arthritis in children and adolescents Sarilumab Juvenile idiopathic arthritis Rheumatology 2023 View  |  Download
Sarizotan for Respiratory Symptoms Associated Rett Syndrome Sarizotan (EMD-128130) Rett syndrome Genetic Disorders , Neurology 2018 View  |  Download
Savolitinib for MET-driven, unresectable and locally advanced or metastatic papillary renal cell carcinoma Savolitinib (AZD6094) Renal cell carcinoma (RCC) Renal Cancer 2019 View  |  Download
Sebetralstat for treating hereditary angioedema Sebetralstat (KVD-900) Hereditary angioedema (HAE) Genetic Disorders , Immunology 2023 View  |  Download
Secukinumab biosimilar for treating plaque psoriasis Secukinumab biosimilar (BAT2306) Plaque psoriasis Dermatology 2024 View  |  Download
Secukinumab for enthesitis-related arthritis and juvenile psoriatic arthritis in children and adolescents from the age of 2 years Secukinumab (Cosentyx; AIN457) Enthesitis-related arthritis , Juvenile psoriatic arthritis Rheumatology 2019 View  |  Download
Secukinumab for hidradenitis suppurativa Secukinumab (Cosentyx; AIN457) Hidradenitis suppurativa (HS) Dermatology 2021 View  |  Download
1 2 88 89 90 91 92 111 112
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications